Skip to content

Study · Randomized controlled trial · 2026

3 results

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.

Zaccardi F, Aroda VR, Arslan EG, Bardtrum L, Goldney J, Ising E, Priyadarshini P, Slater T, Davies MJ

Diabetes, obesity & metabolism17 Apr 2026

PMID41994903 (opens in a new tab)PMCIDPMC13243996 (opens in a new tab)DOI10.1111/dom.70770 (opens in a new tab)PepBankPUB-41994903
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

AimsYoung adults (aged ≤ 40 years) are underrepresented in clinical trials that investigate interventions for those living with Type 2 diabetes (T2D). This study evaluated the efficacy of semaglutide treatment in young adults with T2D by examining the effects on HbA1c and body weight (BW) during the SUSTAIN and PIONEER programmes compared to placebo and active comparators, according to age at study enrolment. This study also assessed aggregated safety data across age subgroups.Materials and methodsThis post hoc analysis of the SUSTAIN (once-weekly subcutaneous administration) and PIONEER (once-daily oral administration) programmes assessed the efficacy of semaglutide treatment in different age subgroups by comparing change in HbA1c and BW between young adults with T2D (≤ 40 years), middle-aged adults with T2D (> 40- ≤ 50 years), and middle older-aged adults with T2D (> 50 years). Selected safety outcomes were assessed, focusing on serious adverse events (SAEs) and gastrointestinal SAEs from the programmes.ResultsFindings indicate a reduction in HbA1c levels and BW in participants across all age subgroups that were treated with semaglutide, particularly in young adults versus other age subgroups. The proportion of participants experiencing SAEs was overall comparable between semaglutide treatment and comparators across age subgroups and administration route.ConclusionsSemaglutide shows notable and consistent efficacy in reducing HbA1c and BW across all age subgroups with T2D, including young adults. Effective glucose- and weight-lowering interventions in people living with T2D at an earlier stage in life may reduce the high risk of future health complications associated with developing T2D as a younger adult.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, semaglutide reduced HbA1c in all age subgroups, particularly in young adults aged 40 years or younger.

    In plain wordsIn adults with type 2 diabetes, semaglutide lowered HbA1c in every age group, most in young adults.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change by age subgroup
    Study

    n: not reported in source

    Comparator
    Placebo and active comparators
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous (SUSTAIN) and oral (PIONEER)As given in this study (human).

    Source sentences

    Summary
    Findings indicate a reduction in HbA1c levels and BW in participants across all age subgroups that were treated with semaglutide, particularly in young adults versus other age subgroups.
    1 context sentence
    Summary · context
    This post hoc analysis of the SUSTAIN (once-weekly subcutaneous administration) and PIONEER (once-daily oral administration) programmes assessed the efficacy of semaglutide treatment in different age subgroups by comparing change in HbA1c and BW between young adults with T2D (≤ 40 years), middle-aged adults with T2D (> 40- ≤ 50 years), and middle older-aged adults with T2D (> 50 years).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, semaglutide reduced body weight in all age subgroups, particularly in young adults aged 40 years or younger.

    In plain wordsIn adults with type 2 diabetes, semaglutide lowered body weight in every age group, most in young adults.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change by age subgroup
    Study

    n: not reported in source

    Comparator
    Placebo and active comparators
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous (SUSTAIN) and oral (PIONEER)As given in this study (human).

    Source sentences

    Summary
    Findings indicate a reduction in HbA1c levels and BW in participants across all age subgroups that were treated with semaglutide, particularly in young adults versus other age subgroups.
    1 context sentence
    Summary · context
    This post hoc analysis of the SUSTAIN (once-weekly subcutaneous administration) and PIONEER (once-daily oral administration) programmes assessed the efficacy of semaglutide treatment in different age subgroups by comparing change in HbA1c and BW between young adults with T2D (≤ 40 years), middle-aged adults with T2D (> 40- ≤ 50 years), and middle older-aged adults with T2D (> 50 years).
  3. 03HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, the proportion with serious adverse events was overall comparable between semaglutide and comparators across age subgroups and administration routes.

    In plain wordsIn adults with type 2 diabetes, serious side effects were about as common with semaglutide as with comparison treatments in every age group.

    Peptide
    Semaglutide
    Outcome
    No significant changeSerious adverse events by age subgroup
    Study

    n: not reported in source

    Comparator
    Placebo and active comparators
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous (SUSTAIN) and oral (PIONEER)As given in this study (human).

    Source sentences

    Summary
    The proportion of participants experiencing SAEs was overall comparable between semaglutide treatment and comparators across age subgroups and administration route.
    1 context sentence
    Summary · context
    This post hoc analysis of the SUSTAIN (once-weekly subcutaneous administration) and PIONEER (once-daily oral administration) programmes assessed the efficacy of semaglutide treatment in different age subgroups by comparing change in HbA1c and BW between young adults with T2D (≤ 40 years), middle-aged adults with T2D (> 40- ≤ 50 years), and middle older-aged adults with T2D (> 50 years).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.